← Return to [[Biliary Tract Cancer Clinical Trials]] ---- Phase III | UK multicenter randomized trial | n=410 | Advanced biliary tract cancer | NEJM 2010 **Valle et al.** Published in New England Journal of Medicine, 2010 Enrollment: 2002–2008 [PubMed Link](https://pubmed.ncbi.nlm.nih.gov/20375404/) --- ### Essential Takeaway ABC-02 established **gemcitabine plus cisplatin (Gem/Cis)** as the first global standard first-line systemic therapy for advanced biliary tract cancer. Compared with gemcitabine alone, Gem/Cis significantly improved: - overall survival - progression-free survival - disease control without substantially increasing toxicity. The trial fundamentally changed the treatment landscape for biliary tract cancer and became the backbone upon which essentially all subsequent BTC systemic therapy trials were built. --- ### Clinical Question Does the addition of cisplatin to gemcitabine improve survival compared with gemcitabine alone in patients with advanced biliary tract cancer? --- ### Population Included: - Locally advanced unresectable BTC - Metastatic BTC - Recurrent BTC Tumor types: - Intrahepatic cholangiocarcinoma - Extrahepatic cholangiocarcinoma - Gallbladder carcinoma - Ampullary carcinoma Performance status: - ECOG 0-2 Importantly, this was one of the first large trials to group biliary tract cancers together under a unified systemic therapy framework. --- ### Study Design Randomized phase III trial. #### Arm 1 — Gemcitabine Alone - Gemcitabine 1000 mg/m² - Days 1, 8, 15 - Every 28 days - Up to 6 cycles #### Arm 2 — Cisplatin + Gemcitabine - Cisplatin 25 mg/m² - Gemcitabine 1000 mg/m² - Days 1 and 8 - Every 21 days - Up to 8 cycles Primary endpoint: - Overall survival (OS) Secondary endpoints: - Progression-free survival (PFS) - Tumor response - Toxicity - Disease control --- ### Key Results ### Overall Survival - 11.7 vs 8.1 months - HR 0.64 - p < 0.001 This represented a major improvement in a disease previously lacking any validated standard systemic regimen. --- ### Progression-Free Survival - 8.0 vs 5.0 months - HR 0.63 - p < 0.001 --- ### Disease Control Rate - 81.4% vs 71.8% - p = 0.049 Tumor control included: - complete response - partial response - stable disease --- ### Subgroup Findings Benefit was observed broadly across: - gallbladder cancer - intrahepatic cholangiocarcinoma - extrahepatic cholangiocarcinoma - metastatic disease - locally advanced disease No subgroup demonstrated loss of treatment effect. --- ### Toxicity Overall toxicity was surprisingly manageable and became one of the most important practical findings of the study. #### Increased with Gem/Cis - neutropenia - anemia #### Similar Between Groups - infections - fatigue - biliary sepsis Importantly, improved efficacy was achieved without major excess serious toxicity. --- ### Interpretation ABC-02 was a landmark trial because it transformed BTC from a disease without a systemic therapy standard into one with a validated first-line regimen. Prior to ABC-02: - chemotherapy use was inconsistent - evidence was limited to small phase II studies - outcomes were poor and heterogeneous ABC-02 definitively established Gem/Cis as the global reference backbone for advanced BTC. The trial also demonstrated that BTC is meaningfully chemosensitive, helping justify future investment in: - combination chemotherapy - molecular profiling - targeted therapy - immunotherapy Virtually every subsequent modern BTC systemic therapy trial used ABC-02 as its control framework. --- ### Important Limitations #### Molecularly Unselected Era The trial predated: - FGFR2 targeting - IDH1 targeting - HER2-directed therapy - MSI/TMB biomarker strategies - immunotherapy combinations BTC was treated as a single biologic entity. --- ### Heterogeneous Disease Grouping Combined: - ICC - EHCC - gallbladder carcinoma - ampullary carcinoma despite important biologic differences. --- ### Modest Absolute Survival Although practice-changing, median OS remained under 1 year. This highlighted the aggressive biology of advanced BTC and the need for improved therapies. --- ### Relationship to TOPAZ-1 TOPAZ-1 later built directly upon the ABC-02 backbone by adding: - durvalumab to Gem/Cis. Thus: - ABC-02 established the chemotherapy backbone - TOPAZ-1 modernized it with immunotherapy Current first-line advanced BTC treatment paradigms are fundamentally rooted in ABC-02. --- ### Current Practice Relevance ABC-02 remains one of the most important systemic therapy trials in HPB oncology. Gem/Cis continues to serve as: - the historical control arm for BTC trials - the chemotherapy backbone for immunotherapy combinations - a foundational reference regimen in advanced BTC Even in the immunotherapy era, the biologic and therapeutic framework established by ABC-02 remains central to BTC management. --- ### Practice Impact ABC-02 established: - Gem/Cis as first-line standard therapy - BTC as a chemosensitive disease - the modern systemic therapy foundation for BTC research